Sanofi pasteur has delivered more H5N1 vaccine to the U.S. government including investigational doses formulated with an adjuvant. Sanofi pasteur has shipped to the U.S. National Institu
A U.S. advisory panel has recommended that drugs used by millions to treat attention deficit hyperactivity disorder (ADHD), should carry a warning of the risk of heart problems.The advice comes despite the lack of clarity over whether the drugs
Following Medicare's approval of its prescription drug discount card, the Pharmacy Care Alliance today announced that its growing network of pharmacies includes more than 31,000 chain and 10,000 independent representing more than 41,000 local pharmacies ac
The Calorie Control Council has stated that a rat study conducted by Italy's Ramazzini Institute is totally contradictory to the extensive scientific research and regulatory reviews conducted on aspartame. The U.S. Food & Drug Administration (FDA)
Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).
Bristol-Myers Squibb Company, Gilead Sciences, Inc. and Merck & Co., Inc. have announced that they a
According to the birth watchdog group the March of Dimes, preventing birth defects from a widely used acne drug is too heavy a burden on doctors, patients and pharmacists.Doctors say that
The Drug Safety Oversight Board, created in February 2005, was originally introduced as a measure to speed up and help regulators respond to signs of unexpected side effects f
Aloe Commodities International, Inc., Carrollton, Texas, is recalling 1600 bottles of Solutions IE Ageless Formula II, Lot numbers P2207 and P2221 because they contain a significantly higher-tha
HHS Secretary Tommy G. Thompson today announced an expedited review process to ensure that the United States is providing safe, effective drugs to developing countries under the President's $15 billion Emergency Plan for AIDS Relief. U.S. Global AIDS Co
Enbrel is the only fully human, anti-TNF receptor approved to reduce the signs and symptoms of RA in patients who had an inadequate response to traditional disease-modifying antirheumatic medicines. The biological product can be used alone as a monotherapy and is administered twice weekly as a subcutaneous injection. Initially the product will be made available to medical institutions participating in an all-patient surveillance program.
"We are pleased with the approval decision. We will make Enbrel available to Japanese patients as soon as possible," said Rune Bremberg, President and Representative Director of Wyeth K.K.
"Following this approval decision, we hope we will be able to support RA patients by providing Enbrel as new treatment option under the co-promotion with Wyeth K.K.," said Yasuchika Hasegawa, President & COO of Takeda.
http://www.takeda.co.jp and http://www.wyeth.jp